Posted by Michael Wonder on 09 Jul 2020
'Xolair’s reimbursement will change treatment paradigm for asthma patients'
9 July 2020 - Novartis Korea will be able to strengthen its position in the severe allergic asthma market with Xolair (ingredient: omalizumab), which has recently received insurance benefits, the company said Thursday.
Professor Kim Tae-bum at Asan Medical Center explains Xolair's reimbursement for severe asthma patients in Korea, during a news conference at the InterContinental Seoul, on Thursday.
Xolair is the first biological product to treat severe asthma, targeting immunoglobulin E.
